Equities Analysts Set Expectations for Theratechnologies Inc.’s FY2024 Earnings (NASDAQ:THTX)

Theratechnologies Inc. (NASDAQ:THTX) – Investment analysts at Cantor Fitzgerald raised their FY2024 earnings estimates for Theratechnologies in a research note issued to investors on Thursday, April 11th. Cantor Fitzgerald analyst L. Chen now expects that the company will post earnings per share of $0.00 for the year, up from their prior estimate of ($0.06). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Theratechnologies’ current full-year earnings is ($0.03) per share.

Theratechnologies Stock Performance

Theratechnologies stock opened at $1.30 on Monday. The company has a 50 day moving average price of $1.47 and a 200 day moving average price of $1.56. Theratechnologies has a 52 week low of $0.88 and a 52 week high of $4.30. The firm has a market capitalization of $31.46 million, a price-to-earnings ratio of -2.13 and a beta of 1.34.

Theratechnologies (NASDAQ:THTX) last issued its earnings results on Wednesday, February 21st. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.16. The business had revenue of $23.45 million for the quarter. During the same period last year, the firm earned ($0.36) EPS.

Hedge Funds Weigh In On Theratechnologies

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in THTX. Virtu Financial LLC boosted its stake in shares of Theratechnologies by 48.8% during the 2nd quarter. Virtu Financial LLC now owns 22,062 shares of the company’s stock valued at $50,000 after buying an additional 7,237 shares during the period. Osaic Holdings Inc. boosted its stake in shares of Theratechnologies by 2.3% during the 2nd quarter. Osaic Holdings Inc. now owns 444,155 shares of the company’s stock valued at $374,000 after buying an additional 10,000 shares during the period. HighTower Advisors LLC acquired a new stake in shares of Theratechnologies during the 1st quarter valued at $34,000. Range Financial Group LLC acquired a new stake in shares of Theratechnologies during the 1st quarter valued at $35,000. Finally, Atria Wealth Solutions Inc. acquired a new stake in shares of Theratechnologies during the 2nd quarter valued at $33,000.

Theratechnologies Company Profile

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.